Flagship Ventures Opportunities Fund I, L.P.
CIK 0001677345 Name as filed on the most recent filing
Filed as Flagship Ventures Opportunities Fund I, L.P. (13)
41 transaction lines · from 13 filings · filed 2018-05-15 to 2022-10-17 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Axcella Health Inc. 4 filings
- ISSUER Evelo Biosciences, Inc. 4 filings
- ISSUER Rubius Therapeutics, Inc. 1 filings
- ISSUER Kaleido Biosciences, Inc. 3 filings
- ISSUER Foghorn Therapeutics Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2022-10-13 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 3,048,780 acquired | 1.64 | 4,999,999.20 | Form 4, filing 0000899243-22-033703 | |
| 2022-10-13 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 2,757,333 acquired | 1.64 | 4,522,026.12 | Form 4, filing 0000899243-22-033703 | |
| 2022-10-13 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 2,743,902 acquired | 1.64 | 4,499,999.28 | Form 4, filing 0000899243-22-033703 | |
| 2022-10-13 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 919,111 acquired | 1.64 | 1,507,342.04 | Form 4, filing 0000899243-22-033703 | |
| 2022-10-13 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 914,634 acquired | 1.64 | 1,499,999.76 | Form 4, filing 0000899243-22-033703 | |
| 2022-05-27 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 13,698,630 acquired | 1.46 | 19,999,999.80 | Form 4, filing 0000899243-22-020533 | |
| 2022-05-27 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 6,849,315 acquired | 1.46 | 9,999,999.90 | Form 4, filing 0000899243-22-020533 | |
| 2022-05-27 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 4,383,561 acquired | 1.46 | 6,399,999.06 | Form 4, filing 0000899243-22-020533 | |
| 2022-05-27 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 1,369,863 acquired | 1.46 | 1,999,999.98 | Form 4, filing 0000899243-22-020533 | |
| 2022-05-27 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 1,095,890 acquired | 1.46 | 1,599,999.40 | Form 4, filing 0000899243-22-020533 | |
| 2022-03-16 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 3,791,623 acquired | 1.91 | 7,241,999.93 | Form 4, filing 0000899243-22-011535 | |
| 2022-03-16 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 1,579,843 acquired | 1.91 | 3,017,500.13 | Form 4, filing 0000899243-22-011535 | |
| 2022-03-16 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 947,905 acquired | 1.91 | 1,810,498.55 | Form 4, filing 0000899243-22-011535 | |
| 2021-03-19 |
Rubius Therapeutics, Inc. RUBY |
P, Open-market purchase | 70,000 acquired | 29.00 | 2,030,000.00 | Form 4, filing 0000899243-21-013179 | |
| 2021-03-19 |
Rubius Therapeutics, Inc. RUBY |
P, Open-market purchase | 70,000 acquired | 29.00 | 2,030,000.00 | Form 4, filing 0000899243-21-013179 | |
| 2021-03-19 |
Rubius Therapeutics, Inc. RUBY |
P, Open-market purchase | 70,000 acquired | 29.00 | 2,030,000.00 | Form 4, filing 0000899243-21-013179 | |
| 2021-02-08 |
Kaleido Biosciences, Inc. KLDO |
P, Open-market purchase | 71,667 acquired | 11.50 | 824,170.50 | Form 4, filing 0000899243-21-005713 | |
| 2021-02-08 |
Kaleido Biosciences, Inc. KLDO |
P, Open-market purchase | 71,667 acquired | 11.50 | 824,170.50 | Form 4, filing 0000899243-21-005713 | |
| 2021-02-08 |
Kaleido Biosciences, Inc. KLDO |
P, Open-market purchase | 71,666 acquired | 11.50 | 824,159.00 | Form 4, filing 0000899243-21-005713 | |
| 2021-02-02 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 46,429 acquired | 15.00 | 696,435.00 | Form 4, filing 0000899243-21-004962 | |
| 2021-02-02 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 37,143 acquired | 15.00 | 557,145.00 | Form 4, filing 0000899243-21-004962 | |
| 2021-02-02 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 37,143 acquired | 15.00 | 557,145.00 | Form 4, filing 0000899243-21-004962 | |
| 2021-02-02 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 9,285 acquired | 15.00 | 139,275.00 | Form 4, filing 0000899243-21-004962 | |
| 2020-10-27 |
Foghorn Therapeutics Inc. FHTX |
P, Open-market purchase | 50,000 acquired | 16.00 | 800,000.00 | Form 4, filing 0000899243-20-029693 | |
| 2020-10-27 |
Foghorn Therapeutics Inc. FHTX |
P, Open-market purchase | 50,000 acquired | 16.00 | 800,000.00 | Form 4, filing 0000899243-20-029693 | |
| 2020-10-27 |
Foghorn Therapeutics Inc. FHTX |
P, Open-market purchase | 50,000 acquired | 16.00 | 800,000.00 | Form 4, filing 0000899243-20-029693 | |
| 2020-06-29 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 1,666,667 acquired | 3.75 | 6,250,001.25 | Form 4, filing 0000899243-20-018150 | |
| 2020-06-29 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 1,333,333 acquired | 3.75 | 4,999,998.75 | Form 4, filing 0000899243-20-018150 | |
| 2020-06-29 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 1,333,333 acquired | 3.75 | 4,999,998.75 | Form 4, filing 0000899243-20-018150 | |
| 2020-06-29 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 333,333 acquired | 3.75 | 1,249,998.75 | Form 4, filing 0000899243-20-018150 | |
| 2020-06-04 |
Kaleido Biosciences, Inc. KLDO |
P, Open-market purchase | 666,667 acquired | 7.50 | 5,000,002.50 | Form 4, filing 0000899243-20-015630 | |
| 2020-06-04 |
Kaleido Biosciences, Inc. KLDO |
P, Open-market purchase | 666,667 acquired | 7.50 | 5,000,002.50 | Form 4, filing 0000899243-20-015630 | |
| 2020-06-04 |
Kaleido Biosciences, Inc. KLDO |
P, Open-market purchase | 666,666 acquired | 7.50 | 4,999,995.00 | Form 4, filing 0000899243-20-015630 | |
| 2020-05-18 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 1,900,000 acquired | 4.75 | 9,025,000.00 | Form 4, filing 0000899243-20-013708 | |
| 2020-05-18 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 1,520,000 acquired | 4.75 | 7,220,000.00 | Form 4, filing 0000899243-20-013708 | |
| 2020-05-18 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 380,000 acquired | 4.75 | 1,805,000.00 | Form 4, filing 0000899243-20-013708 | |
| 2019-05-13 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 500,000 acquired | 20.00 | 10,000,000.00 | Form 4, filing 0001104659-19-029735 | |
| 2019-03-04 |
Kaleido Biosciences, Inc. KLDO |
P, Open-market purchase | 333,333 acquired | 15.00 | 4,999,995.00 | Form 4, filing 0000899243-19-006455 | |
| 2019-03-04 |
Kaleido Biosciences, Inc. KLDO |
P, Open-market purchase | 333,333 acquired | 15.00 | 4,999,995.00 | Form 4, filing 0000899243-19-006455 | |
| 2019-03-04 |
Kaleido Biosciences, Inc. KLDO |
P, Open-market purchase | 266,667 acquired | 15.00 | 4,000,005.00 | Form 4, filing 0000899243-19-006455 | |
| 2018-05-11 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 281,250 acquired | 16.00 | 4,500,000.00 | Form 4, filing 0000899243-18-013013 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Flagship Ventures Opportunities Fund I, L.P., insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001677345
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6